Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers-Reference-Cited by-同舟云学术

Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers

Published:2020-05-21 Issue:6 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Wu Junzhen¹²³,Cao Guoying²³⁴,Wu Hailan¹²³,Chen Yuancheng²³⁴^ORCID,Guo Beining¹²³,Wu Xiaojie²³⁴,Yu Jicheng²³⁴,Ni Kanhong⁵,Qian Jin⁵,Wang Li⁵,Wu Jufang¹²³⁴,Wang Yu¹²³,Yuan Hong¹⁶,Zhang Jing¹²³⁴,Xi Yuewen⁵

Affiliation:

1. Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China

2. Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China

3. National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China

4. Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China

5. Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China

6. MicuRx Pharmaceuticals, Inc., Hayward, California, USA

Abstract

Contezolid (MRX-I), a new oxazolidinone, is an antibiotic in development for treating complicated skin and soft tissue infections caused by resistant Gram-positive bacteria. This was a thorough QT study conducted in 52 healthy subjects who were administered oral contezolid at a therapeutic (800 mg) dose, a supratherapeutic (1,600 mg) dose, placebo, and oral moxifloxacin at 400 mg in four separate treatment periods. The pharmacokinetic profile of contezolid was also evaluated.

Funder

The Major Research and Development Project of Innovative Drugs, Ministry of Science and Technology of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02158-19

Reference23 articles.

1. The role of methicillin-resistant Staphylococcus aureus in skin and soft tissue infections

2. Vancomycin-Resistant Enterococci: A Review of Antimicrobial Resistance Mechanisms and Perspectives of Human and Animal Health

3. Linezolid: The First Oxazolidinone Antimicrobial